HSP90 and the chaperoning of cancer
The DOI matches its Crossref record; 148 of the 149 references it cites were found in a registry or an index.
Abstract
Standing watch over the proteome, molecular chaperones are an ancient and evolutionarily conserved class of proteins that guide the normal folding, intracellular disposition and proteolytic turnover of many of the key regulators of cell growth, differentiation and survival. This essential guardian function is subverted during oncogenesis to allow malignant transformation and to facilitate rapid somatic evolution. Pharmacologically 'bribing' the essential guard duty of the chaperone HSP90 (heat-shock protein of 90 kDa) seems to offer a unique anticancer strategy of considerable promise.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“HSP90AB1 is commonly overexpressed in a variety of cancers, with this upregulation typically linked to poor prognostic outcomes and increased resistance to standard chemotherapy and radiotherapy treatments [12, 42, 43].”
From Celastrol attenuates the invasion and migration and augments the anticancer effects of olaparib in prostate cancer (2024) · cites this paper as [43]
In the citing paper
“This role as a potentiator for genetic variation has been observed in fungi as well as mammalian cancer cells20,88,135,136.”
From Fungal Hsp90: a biological transistor that tunes cellular outputs to thermal inputs (2012) · cites this paper as [88]
In the citing paper
“Second, Hsp90 can enable the phenotypic effects of new mutations either by stabilizing mutant regulators or by stabilizing non-mutant regulators that mediate signalling required for adaptation.”
From Fungal Hsp90: a biological transistor that tunes cellular outputs to thermal inputs (2012) · cites this paper as [88]
Citations
Cites
Hsp90 as a capacitor for morphological evolution
Rutherford, S. L., & Lindquist, S. (1998) · Nature · doi:10.1038/24550 · Cited by 2,270 · cited 1×
“melanogaster and Arabidopsis thaliana model systems that HSP90 can conceal inherent genetic variation within populations of organism”
BackgroundSelf-citationWhitesell, L., Mimnaugh, E. G., De Costa, B., Myers, C. E., & Neckers, L. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.18.8324 · Cited by 1,444
Self-citationA high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors
Kamal, A., Thao, L., Sensintaffar, J., Zhang, L., Boehm, M. F., Fritz, L. C., & Burrows, F. J. (2003) · Nature · doi:10.1038/nature01913 · Cited by 1,387 · cited 1×
“By contrast, in normal cells, there is a substantial pool of free HSP90 dimers that have low ATPase activity and low drug affinit”
BackgroundHsp90 as a capacitor of phenotypic variation
Queitsch, C., Sangster, T. A., & Lindquist, S. (2002) · Nature · doi:10.1038/nature749 · Cited by 1,372
Self-citationStebbins, C. E., Russo, A. A., Schneider, C., Rosen, N., Hartl, F. U., & Pavletich, N. P. (1997) · Cell · doi:10.1016/s0092-8674(00)80203-2 · Cited by 1,364
Prodromou, C., Roe, S. M., O'Brien, R., Ladbury, J. E., Piper, P. W., & Pearl, L. H. (1997) · Cell · doi:10.1016/s0092-8674(00)80314-1 · Cited by 1,265
Structure of TPR Domain–Peptide Complexes
Scheufler, C., Brinker, A., Bourenkov, G., Pegoraro, S., Moroder, L., Bartunik, H., Hartl, F. U., & Moarefi, I. (2000) · Cell · doi:10.1016/s0092-8674(00)80830-2 · Cited by 1,188
Role of the Heat Shock Response and Molecular Chaperones in Oncogenesis and Cell Death
Jolly, C. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.19.1564 · Cited by 1,048 · cited 1×
“Several detailed reviews are available that address the molecular and cellular biology of the heat-shock respons”
BackgroundThe 90-kDa Molecular Chaperone Family
Csermely, P., Schnaider, T., So″ti, C., Prohászka, Z., & Nardai, G. (1998) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00013-8 · Cited by 1,028
Roe, S. M., Prodromou, C., O'Brien, R., Ladbury, J. E., Piper, P. W., & Pearl, L. H. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm980403y · Cited by 1,004 · cited 1×
“Drug binding at the N-terminus of HSP90 has now been shown to alter many of its normal function”
Background
Research works printed but not linked: 2
- McCollum, A., Toft, D. O. & Erlichman, C. Geldanamycin enhances cisplatin cytotoxicity through loss of Akt activation in A549 cells. Clin. Cancer Res. 9 (Suppl.), 6178 (2003).
- Barbosa, J. A. et al. Discovery of novel small molecule Hsp90 complex inhibitors using a forward chemical genetics approach. Clin. Cancer Res. 9 (Suppl.), 6176 (2003).
Cited by
Items 101–200 of 1,008
Yoshida, S., Tsutsumi, S., Muhlebach, G., Sourbier, C., Lee, M.-J., Lee, S., Vartholomaiou, E., Tatokoro, M., Beebe, K., Miyajima, N., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1220659110 · Cited by 279
“However, these inhibitors do not distinguish between HSP90 and TRAP1 (11), and TRAP1 expression in cancer is variable but HSP90 comprises as much as 5% of a cancer cell’s protein complement (12).”
BackgroundHSP27, 70 and 90, anti-apoptotic proteins, in clinical cancer therapy
WANG, X., CHEN, M., ZHOU, J., & ZHANG, X. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2399 · Cited by 269
Extracellular heat shock protein‐90α: linking hypoxia to skin cell motility and wound healing
Li, W., Li, Y., Guan, S., Fan, J., Cheng, C., Bright, A. M., Chinn, C., Chen, M., & Woodley, D. T. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601579 · Cited by 280
Heat shock proteins and heat shock factor 1 in carcinogenesis and tumor development: an update
Ciocca, D. R., Arrigo, A. P., & Calderwood, S. K. (2013) · Archives of Toxicology · doi:10.1007/s00204-012-0918-z · Cited by 265
“Consequently, inhibition of Hsp90 expression triggers apoptosis through a general knockdown of procancerous signaling pathways (Whitesell and Lindquist 2005).”
The Ribosome as a Hub for Protein Quality Control
Pechmann, S., Willmund, F., & Frydman, J. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.01.020 · Cited by 268
“In addition, deregulation of chaperone networks is exploited for uncontrolled cell proliferation in cancers (Whitesell and Lindquist, 2005) and helps drive aneuploidy (Oromendia et al.”
BackgroundWoodhead, A. J., Angove, H., Carr, M. G., Chessari, G., Congreve, M., Coyle, J. E., Cosme, J., Graham, B., Day, P. J., Downham, R., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100060b · Cited by 264
The Mitochondrial Chaperone TRAP1 Promotes Neoplastic Growth by Inhibiting Succinate Dehydrogenase
Sciacovelli, M., Guzzo, G., Morello, V., Frezza, C., Zheng, L., Nannini, N., Calabrese, F., Laudiero, G., Esposito, F., Landriscina, M., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.019 · Cited by 264
Characterization of PINK1 processing, stability, and subcellular localization
Lin, W., & Kang, U. J. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05398.x · Cited by 262
The regulatory mechanism of Hsp90α secretion and its function in tumor malignancy
Wang, X., Song, X., Zhuo, W., Fu, Y., Shi, H., Liang, Y., Tong, M., Chang, G., & Luo, Y. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908151106 · Cited by 259
Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance
Johnson, N., Johnson, S. F., Yao, W., Li, Y.-C., Choi, Y.-E., Bernhardy, A. J., Wang, Y., Capelletti, M., Sarosiek, K. A., Moreau, L. A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1305170110 · Cited by 265
“Because HSP90 has been implicated in the folding of cancer-related mutant proteins (15), we investigated the dependency of BRCA1 mutant protein levels on HSP90 activity.”
BackgroundThe multicellular tumor spheroid model for high-throughput cancer drug discovery
LaBarbera, D. V., Reid, B. G., & Yoo, B. H. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2012.708334 · Cited by 255
“Using this model the authors showed that 17-N-allylamino17-demethoxygeldanamycin, a specific inhibitor of heat shock protein 90 (HSP90), a molecular chaperone and established cancer target [93], blocked the invasive potential of U-87 spheroids after a 72-hour treatment.”
MethodGeller, R., Vignuzzi, M., Andino, R., & Frydman, J. (2007) · Genes & Development · doi:10.1101/gad.1505307 · Cited by 263
“This result supports previous findings that GA inhibits the p23–Hsp90 interaction, thus blocking progression through the Hsp90 chaperone cycle (Young et al. 2001; Picard 2002; Wegele et al. 2004; Ali et al. 2006).”
BackgroundResultBirbo, B., Madu, E. E., Madu, C. O., Jain, A., & Lu, Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910317 · Cited by 244
“This upregulation of HSP90 is said to be what enables tumor cells to survive the harsh microenvironments by allowing for the persistence of mutations that spur malignancy [10].”
BackgroundExploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors
De Raedt, T., Walton, Z., Yecies, J. L., Li, D., Chen, Y., Malone, C. F., Maertens, O., Jeong, S. M., Bronson, R. T., Lebleu, V., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.08.014 · Cited by 258
“HSP90 maintains protein homeostasis by folding newly synthesized and misfolded proteins, assembling and dissembling protein complexes, and resolving protein aggregates (Whitesell and Lindquist, 2005).”
Conservation genetics and the resilience of reef‐building corals
VAN OPPEN, M. J. H., & GATES, R. D. (2006) · Molecular Ecology · doi:10.1111/j.1365-294x.2006.03026.x · Cited by 258
“…health against a backdrop of ever changing environmental conditions is fundamental to life, and many of the genes and proteins involved in the maintenance of homeostasis and stress amelioration are evolutionarily conserved (Parsell & Lindquist 1993; Downs et al. 1998; Whitesell & Lindquist 2005).”
BackgroundSingh, M. K., Shin, Y., Ju, S., Han, S., Choe, W., Yoon, K.-S., Kim, S. S., & Kang, I. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084209 · Cited by 221
Heat shock protein 90 in neurodegenerative diseases
Luo, W., Sun, W., Taldone, T., Rodina, A., & Chiosis, G. (2010) · Molecular Neurodegeneration · doi:10.1186/1750-1326-5-24 · Cited by 248
“Roles of Hsp90 in neurodegeneration Hsp90 is a molecular chaperone with important roles in maintaining the functional stability and viability of cells under a transforming pressure [1-3].”
BackgroundThe heat shock factor family and adaptation to proteotoxic stress
Fujimoto, M., & Nakai, A. (2010) · The FEBS Journal · doi:10.1111/j.1742-4658.2010.07827.x · Cited by 246
Molecular chaperones and proteostasis regulation during redox imbalance
Niforou, K., Cheimonidou, C., & Trougakos, I. P. (2014) · Redox Biology · doi:10.1016/j.redox.2014.01.017 · Cited by 250
“Among the proteins that are substrates of the HSP90 system are hormone receptors, kinases and oncogenic proteins [49].”
BackgroundHsp90 and co‐chaperones twist the functions of diverse client proteins
Zuehlke, A., & Johnson, J. L. (2010) · Biopolymers · doi:10.1002/bip.21292 · Cited by 251
The large conformational changes of Hsp90 are only weakly coupled to ATP hydrolysis
Mickler, M., Hessling, M., Ratzke, C., Buchner, J., & Hugel, T. (2009) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1557 · Cited by 254
“In addition, it has an important role in diseases, especially cancer, where the chaperoning of mutated and overexpressed oncoproteins is crucia”
BackgroundWTAP is a novel oncogenic protein in acute myeloid leukemia
Bansal, H., Yihua, Q., Iyer, S. P., Ganapathy, S., Proia, D., Penalva, L. O., Uren, P. J., Suresh, U., Carew, J. S., Karnad, A. B., et al. (2014) · Leukemia · doi:10.1038/leu.2014.16 · Cited by 243
Apoptosis Versus Cell Differentiation: Role of Heat Shock Proteins HSP90, HSP70 and HSP27
Lanneau, D., de Thonel, A., Maurel, S., Didelot, C., & Garrido, C. (2007) · Prion · doi:10.4161/pri.1.1.4059 · Cited by 235
ALK inhibitors in non-small cell lung cancer: crizotinib and beyond.
Awad, M. M., & Shaw, A. T. (2014) · PubMed · Cited by 264
Pratt, W. B., Gestwicki, J. E., Osawa, Y., & Lieberman, A. P. (2015) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124332 · Cited by 239
“The rationale in cancer treatment is to eliminate or decrease the level of many Hsp90 client oncoproteins that are critical in the genesis and maintenance of malignancy by treating with Hsp90 inhibitors (23).”
Schulz-Heddergott, R., Stark, N., Edmunds, S. J., Li, J., Conradi, L.-C., Bohnenberger, H., Ceteci, F., Greten, F. R., Dobbelstein, M., & Moll, U. M. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.07.004 · Cited by 238
“The HSP90/HDAC6 chaperone machinery, which is ubiquitously activated in cancer compared with normal tissues (Whitesell and Lindquist, 2005), is a major determinant of mutp53 stabilization by providing protection from degradation by E3 ubiquitin ligases such as Mdm2 and CHIP (Blagosklonny et al.”
BackgroundHsp90-Cdc37 Chaperone Complex Regulates Ulk1- and Atg13-Mediated Mitophagy
Joo, J. H., Dorsey, F. C., Joshi, A., Hennessy-Walters, K. M., Rose, K. L., McCastlain, K., Zhang, J., Iyengar, R., Jung, C. H., Suen, D.-F., et al. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.06.018 · Cited by 232
“First, it has been proposed that the destabilization of proteins associated with growth in the hypoxic, nutrient-deprived tumor milieu is compensated by increased expression of Hsp90 and its cochaperones (Whitesell and Lindquist, 2005).”
Targeting tumour-supportive cellular machineries in anticancer drug development
Dobbelstein, M., & Moll, U. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4201 · Cited by 229
Jensen, M. R., Schoepfer, J., Radimerski, T., Massey, A., Guy, C. T., Brueggen, J., Quadt, C., Buckler, A., Cozens, R., Drysdale, M. J., et al. (2008) · Breast Cancer Research · doi:10.1186/bcr1996 · Cited by 229
“This makes patient stratification exceedingly difficult, as discussed elsewhere [33].”
BackgroundYing, W., Du, Z., Sun, L., Foley, K. P., Proia, D. A., Blackman, R. K., Zhou, D., Inoue, T., Tatsuta, N., Sang, J., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0755 · Cited by 229
“Aswith other physiologic processes that become coopted by tumor cells, it is now clear that the chaperoning functions of Hsp90 can become subverted during tumorigenesis to facilitatemalignant progression (1).”
BackgroundSydor, J. R., Normant, E., Pien, C. S., Porter, J. R., Ge, J., Grenier, L., Pak, R. H., Ali, J. A., Dembski, M. S., Hudak, J., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0608372103 · Cited by 231
Drug discovery from natural products
Gullo, V. P., McAlpine, J., Lam, K. S., Baker, D., & Petersen, F. (2006) · Journal of Industrial Microbiology & Biotechnology · doi:10.1007/s10295-006-0107-2 · Cited by 222
“The cancer target, HSP90 is a molecular chaperonin that is responsible for maintaining the correct folding and stability of over 100 client proteins including many proteins in cancer survival, such as the estrogen receptor, androgen receptor, HIF-1(, Raf-1, Akt/PKB, Cdk4, and ErbB2 [22, 29].”
BackgroundRole of Acetylation and Extracellular Location of Heat Shock Protein 90α in Tumor Cell Invasion
Yang, Y., Rao, R., Shen, J., Tang, Y., Fiskus, W., Nechtman, J., Atadja, P., & Bhalla, K. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0644 · Cited by 221
“It exerts an essential role in proper folding and in maintaining the active conformation, intracellular disposition, and proteolytic turnover of a large number of the progrowth and prosurvival substrate client oncoproteins in cancer cells (1).”
BackgroundInhibiting the transcription factor HSF1 as an anticancer strategy
Whitesell, L., & Lindquist, S. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220902832697 · Cited by 222
“The recent entry of numerous inhibitors of heat shock protein 90 (HSP90) into cancer clinical trials serves as a welcome milestone on the long road to understanding the role of heat-shock proteins (HSP) in cancer and how they might be targeted for therapeutic benefit [1,2] .”
BackgroundSelf-citationBroad action of Hsp90 as a host chaperone required for viral replication
Geller, R., Taguwa, S., & Frydman, J. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.11.007 · Cited by 224
“Among the Hsp90 clientele identified to date are many proteins involved in signal transduction and cell division, including numerous proteins related to tumorigenesis [26,27].”
BackgroundHsp90, an unlikely ally in the war on cancer
Barrott, J. J., & Haystead, T. A. J. (2013) · The FEBS Journal · doi:10.1111/febs.12147 · Cited by 215
Firefly luciferase mutants as sensors of proteome stress
Gupta, R., Kasturi, P., Bracher, A., Loew, C., Zheng, M., Villella, A., Garza, D., Hartl, F. U., & Raychaudhuri, S. (2011) · Nature Methods · doi:10.1038/nmeth.1697 · Cited by 219
Adaptation to Oxidative Stress, Chemoresistance, and Cell Survival
Landriscina, M., Maddalena, F., Laudiero, G., & Esposito, F. (2009) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.2692 · Cited by 217
“It has been proposed that, because of its restricted repertoire of client proteins, mainly kinases and signaling molecules, HSP90 chaperones occupy a critical role in cellular homeostasis (172, 177).”
Paraptosis in the anti-cancer arsenal of natural products
Lee, D., Kim, I. Y., Saha, S., & Choi, K. S. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.01.003 · Cited by 215
PARP inhibitor combination therapy
Dréan, A., Lord, C. J., & Ashworth, A. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.10.010 · Cited by 212
Structure of Hsp90–Hsp70–Hop–GR reveals the Hsp90 client-loading mechanism
Wang, R. Y.-R., Noddings, C. M., Kirschke, E., Myasnikov, A. G., Johnson, J. L., & Agard, D. A. (2022) · Nature · doi:10.1038/s41586-021-04252-1 · Cited by 220
The diverse consequences of aneuploidy
Chunduri, N. K., & Storchová, Z. (2019) · Nature Cell Biology · doi:10.1038/s41556-018-0243-8 · Cited by 210
Structural and functional complexity of HSP90 in cellular homeostasis and disease
Chiosis, G., Digwal, C. S., Trepel, J. B., & Neckers, L. (2023) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-023-00640-9 · Cited by 202
“HSP90 is best known as a foldase, that is, a protein that guides a set of ‘client’ proteins by ensuring that their folding and assembly occur correctly 10–13 .”
BackgroundSang, J., Acquaviva, J., Friedland, J. C., Smith, D. L., Sequeira, M., Zhang, C., Jiang, Q., Xue, L., Lovly, C. M., Jimenez, J.-P., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0440 · Cited by 208
Heat Shock Protein 90 Inhibitors: An Update on Achievements, Challenges, and Future Directions
Li, L., Wang, L., You, Q.-D., & Xu, X.-L. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00940 · Cited by 202
Endocytic downregulation of ErbB receptors: mechanisms and relevance in cancer
Roepstorff, K., Grøvdal, L., Grandal, M., Lerdrup, M., & van Deurs, B. (2008) · Histochemistry and Cell Biology · doi:10.1007/s00418-008-0401-3 · Cited by 202
“HSP90 has gained a lot of attention due to the involvement of many of its clients in cancers, and several inhibitors are being tested in clinical trials, including the Geldanamycin derivative 17-AAG (Goetz et al. 2003; Solit and Chiosis 2008; Vastag 2006; Whitesell and Lindquist 2005).”
BackgroundPratt, W. B., Morishima, Y., Peng, H.-M., & Osawa, Y. (2010) · Experimental Biology and Medicine · doi:10.1258/ebm.2009.009250 · Cited by 200
Maximizing the Therapeutic Potential of HSP90 Inhibitors
Butler, L. M., Ferraldeschi, R., Armstrong, H. K., Centenera, M. M., & Workman, P. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0234 · Cited by 208
“Cancer cells also rely on HSP90 to stabilize mutated, fused, and overexpressed oncoproteins, such as vSRC, HER2, BCR-ABL, B-RAF, and ELM4ALK (12, 14).”
BackgroundCharacterization of Celastrol to Inhibit Hsp90 and Cdc37 Interaction
Zhang, T., Li, Y., Yu, Y., Zou, P., Jiang, Y., & Sun, D. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.051532 · Cited by 199
New therapeutic strategies to treat human cancers expressing mutant p53 proteins
Blandino, G., & Di Agostino, S. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0705-7 · Cited by 201
Small-molecule proteostasis regulators for protein conformational diseases
Calamini, B., Silva, M. C., Madoux, F., Hutt, D. M., Khanna, S., Chalfant, M. A., Saldanha, S. A., Hodder, P., Tait, B. D., Garza, D., et al. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.763 · Cited by 199
Gasdermin-B Promotes Invasion and Metastasis in Breast Cancer Cells
Hergueta-Redondo, M., Sarrió, D., Molina-Crespo, Á., Megias, D., Mota, A., Rojo-Sebastian, A., García-Sanz, P., Morales, S., Abril, S., Cano, A., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090099 · Cited by 201
Minguet, J., Smith, K. H., & Bramlage, P. (2016) · International Journal of Cancer · doi:10.1002/ijc.29915 · Cited by 194
“Heat shock protein (HSP)290 has been implicated in the protection of tumours and the stabilisation of the genetic mutations that often characterise them, effectively acting as a “biochemical buffer” within the tumour microenvironment.(139) In relation to lung cancer, HSP-90 is known to act as a molecular chaperone to…”
BackgroundEGFR-TKI resistance in NSCLC patients: mechanisms and strategies.
Lin, Y., Wang, X., & Jin, H. (2014) · Europe PMC (PubMed Central) · Cited by 230
Swe1Wee1-Dependent Tyrosine Phosphorylation of Hsp90 Regulates Distinct Facets of Chaperone Function
Mollapour, M., Tsutsumi, S., Donnelly, A. C., Beebe, K., Tokita, M. J., Lee, M.-J., Lee, S., Morra, G., Bourboulia, D., Scroggins, B. T., et al. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.01.005 · Cited by 196
“Therefore Hsp90 has become an attractive target for new cancer therapeutics (Whitesell and Lindquist, 2005; Workman and de Billy, 2007), even though a full understanding of the chaperoning requirements of discrete clients remains lacking.”
Huang, K. H., Veal, J. M., Fadden, R. P., Rice, J. W., Eaves, J., Strachan, J.-P., Barabasz, A. F., Foley, B. E., Barta, T. E., Ma, W., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900230j · Cited by 192
Pacey, S., Wilson, R. H., Walton, M., Eatock, M. M., Hardcastle, A., Zetterlund, A., Arkenau, H.-T., Moreno-Farre, J., Banerji, U., Roels, B., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1927 · Cited by 190
“client proteins [1-4] including the androgen receptor and oncogenic kinases such as”
Orlova, A., Tolmachev, V., Pehrson, R., Lindborg, M., Tran, T., Sandström, M., Nilsson, F. Y., Wennborg, A., Abrahmsén, L., & Feldwisch, J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2887 · Cited by 193
“Thus, inhibition of HSP90 leads to increased proteasome-mediated degradation of client proteins, which in turn leads to inhibition of cell proliferation and finally to apoptosis (22).”
BackgroundLIMIT is an immunogenic lncRNA in cancer immunity and immunotherapy
Li, G., Kryczek, I., Nam, J., Li, X., Li, S., Li, J., Wei, S., Grove, S., Vatan, L., Zhou, J., et al. (2021) · Nature Cell Biology · doi:10.1038/s41556-021-00672-3 · Cited by 197
“Although HSP90 inhibitor suppressed the expression of HSP90 client proteins (such as RAF1, BCL2 and CDK4 33 ), overexpression of GBPs failed to do so (Fig.”
Tel2 structure and function in the Hsp90-dependent maturation of mTOR and ATR complexes
Takai, H., Xie, Y., de Lange, T., & Pavletich, N. P. (2010) · Genes & Development · doi:10.1101/gad.1956410 · Cited by 189
Atkinson, R. L., Zhang, M., Diagaradjane, P., Peddibhotla, S., Contreras, A., Hilsenbeck, S. G., Woodward, W. A., Krishnan, S., Chang, J. C., & Rosen, J. M. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001447 · Cited by 190
“Heat shock proteins may account for differences in DNA repair and tumor phenotype after treatment Heat shock proteins (HSPs) are traditionally expressed at a higher level in cancer compared to normal cells and have been linked to treatment resistance (29).”
BackgroundProtein Homeostasis in Models of Aging and Age-Related Conformational Disease
Kikis, E. A., Gidalevitz, T., & Morimoto, R. I. (2010) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4419-7002-2_11 · Cited by 185
Rao, R., Fiskus, W., Yang, Y., Lee, P., Joshi, R., Fernandez, P., Mandawat, A., Atadja, P., Bradner, J. E., & Bhalla, K. (2008) · Blood · doi:10.1182/blood-2008-03-143644 · Cited by 188
“Specifically, we have determined that induction of hsp90 hyperacetylation (1) enhances the binding of 17-AAG to hsp90, (2) augments 17-AAG–mediated inhibition of ATP and cochaperone binding to hsp90, and (3) promotes 17-AAG–mediated depletion of hsp90 client proteins.”
BackgroundLindquist, S. L., & Kelly, J. W. (2011) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a004507 · Cited by 190
Self-citationChaperoning steroid hormone action
Picard, D. (2006) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2006.06.003 · Cited by 189
Murray, C. W., Carr, M. G., Callaghan, O., Chessari, G., Congreve, M., Cowan, S., Coyle, J. E., Downham, R., Figueroa, E., Frederickson, M., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100059d · Cited by 184
TRAP-1, the mitochondrial Hsp90
Altieri, D. C., Stein, G. S., Lian, J. B., & Languino, L. R. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.08.007 · Cited by 186
Recent developments in epigenetic cancer therapeutics: clinical advancement and emerging trends
Nepali, K., & Liou, J.-P. (2021) · Journal of Biomedical Science · doi:10.1186/s12929-021-00721-x · Cited by 178
Secondary Metabolites from Higher Fungi: Discovery, Bioactivity, and Bioproduction
Zhong, J.-J., & Xiao, J.-H. (2009) · Biotechnology in China I · doi:10.1007/10_2008_26 · Cited by 178
“Furthermore, Hsp90 is recognized to play a critical role in the cancer phenotype and provide a particularly effective target for cancer chemotherapy because of its importance in maintaining the function of key oncogenic client proteins [177, 178].”
BackgroundMolecular chaperones and protein kinase quality control
Caplan, A. J., Mandal, A. K., & Theodoraki, M. A. (2007) · Trends in Cell Biology · doi:10.1016/j.tcb.2006.12.002 · Cited by 185
The mechanism of Hsp70 chaperones: (entropic) pulling the models together
Goloubinoff, P., & Rios, P. D. L. (2007) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2007.06.008 · Cited by 182
HSP90 inhibitors and cancer: Prospects for use in targeted therapies (Review)
Li, Z.-N., & Luo, Y. (2022) · Oncology Reports · doi:10.3892/or.2022.8443 · Cited by 173
“The HSP90 chaperone machinery plays a crucial role in protecting over‑ expressed and mutated proteins from misfolding and inducing their degradation where appropriate (3).”
Old and New Approaches to Target the Hsp90 Chaperone
Sanchez, J., Carter, T. R., Cohen, M. S., & Blagg, B. S. J. (2020) · Current Cancer Drug Targets · doi:10.2174/1568009619666191202101330 · Cited by 183
Li, Y., Zhang, T., Schwartz, S. J., & Sun, D. (2009) · Drug Resistance Updates · doi:10.1016/j.drup.2008.12.002 · Cited by 176
“Coadministration of 17-AAG and proteasome inhibitors such as bortezomib has also been reported to produce synergistic anti-cancer effects, which might result from the concomitant increase in protein misfolding and impairment of proteasome-dependent clearance (Whitesell and Lindquist, 2005).”
BackgroundNew wirings in the survivin networks
Altieri, D. C. (2008) · Oncogene · doi:10.1038/onc.2008.303 · Cited by 181
“Hsp90 is broadly overexpressed in most tumors, where it exhibits a much higher ATPase activity in vivo (Whitesell and Lindquist, 2005).”
Protein Homeostasis and the Phenotypic Manifestation of Genetic Diversity: Principles and Mechanisms
Jarosz, D. F., Taipale, M., & Lindquist, S. (2010) · Annual Review of Genetics · doi:10.1146/annurev.genet.40.110405.090412 · Cited by 179
Self-citationPrat, A., & Baselga, J. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1179 · Cited by 177
“Finally, inhibitors of heat shock protein 90, such as KOS-953 (Tanespimycin, Kosan Biosciences Inc, Hayward, CA), promote ubiquitination and degradation of HER2”
BackgroundGaron, E. B., Sawcer, D., Vernier, P. T., Tang, T., Sun, Y., Marcu, L., Gundersen, M. A., & Koeffler, H. P. (2007) · International Journal of Cancer · doi:10.1002/ijc.22723 · Cited by 176
“below the threshold of 42 C where heat shock proteins are activated.(29) Thus, this study demonstrates that at least the AsPC-1 xenografts of pancreatic cancer cells respond to nanoelectropulses of this duration by a mechanism not involving the traditional heat shock response.”
BackgroundBrough, P. A., Barril, X., Borgognoni, J., Chene, P., Davies, N. G. M., Davis, B., Drysdale, M. J., Dymock, B., Eccles, S. A., Garcia-Echeverria, C., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900357y · Cited by 173
Tan, S., Khumalo, N., & Bayat, A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01810 · Cited by 173
“HSP90 increases in response to cellular stresses to increase cell survival (97) and is upregulated in keloids (98).”
BackgroundKirschning, A., & Hahn, F. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201107386 · Cited by 169
Lundgren, K., Zhang, H., Brekken, J., Huser, N., Powell, R. E., Timple, N., Busch, D. J., Neely, L., Sensintaffar, J. L., Yang, Y.-C., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0758 · Cited by 173
“Mutated proteins are particularly dependent on Hsp90 for the maintenance of the active conformation (2, 3).”
BackgroundHeat shock protein 90 inhibitors in the treatment of cancer: current status and future directions
Jhaveri, K., Ochiana, S. O., Dunphy, M. P., Gerecitano, J. F., Corben, A. D., Peter, R. I., Janjigian, Y. Y., Gomes-DaGama, E. M., Koren, J., Modi, S., et al. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.902442 · Cited by 172
“, HER2amplified breast cancer, because HER2 is a sensitive HSP90 onco-client, Figure 1) [1-4].”
BackgroundInfluentialDeubiquitinases Maintain Protein Homeostasis and Survival of Cancer Cells upon Glutathione Depletion
Harris, I. S., Endress, J. E., Coloff, J. L., Selfors, L. M., McBrayer, S. K., Rosenbluth, J. M., Takahashi, N., Dhakal, S., Koduri, V., Oser, M. G., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.01.020 · Cited by 170
“These stresses include, but are not limited to, oxidative stress (Chandel and Tuveson, 2014), ER stress (Wang and Kaufman, 2014) and proteotoxic stress (Dai, 2018; Whitesell and Lindquist, 2005).”
BackgroundHsp90 is regulated by a switch point in the C‐terminal domain
Retzlaff, M., Stahl, M., Eberl, H. C., Lagleder, S., Beck, J., Kessler, H., & Buchner, J. (2009) · EMBO reports · doi:10.1038/embor.2009.153 · Cited by 171
“The possibility to block the essential ATPase activity of Hsp90 (Obermann et al, 1998; Panaretou et al, 1998) through specific inhibitors makes Hsp90 an interesting target for anti-cancer therapy (Whitesell & Lindquist, 2005).”
BackgroundGeldanamycin and its anti-cancer activities
Fukuyo, Y., Hunt, C. R., & Horikoshi, N. (2010) · Cancer Letters · doi:10.1016/j.canlet.2009.07.010 · Cited by 167
Musolino, C., Allegra, A., Innao, V., Allegra, A. G., Pioggia, G., & Gangemi, S. (2017) · Mediators of Inflammation · doi:10.1155/2017/1852517 · Cited by 168
“Furthermore, its action appears to be essential for cancer cells to preserve an abnormal homeostasis, defending themselves against the microenvironment, which is acidotic, hypoxic, and nutrient-deprived [247, 248].”
BackgroundShimamura, T., Perera, S. A., Foley, K. P., Sang, J., Rodig, S. J., Inoue, T., Chen, L., Li, D., Carretero, J., Li, Y.-C., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2967 · Cited by 164
“HSP90 is essential for the post-translational conformational maturation and stability of client proteins, including protein kinases, steroid receptors and transcription factors, many of which are important for the proliferation and survival of cancer cells (2, 3).”
Targeting the DNA Damage Response in Cancer
Ljungman, M. (2009) · Chemical Reviews · doi:10.1021/cr900047g · Cited by 163
Chatterjee, M., Andrulis, M., Stuhmer, T., Muller, E., Hofmann, C., Steinbrunn, T., Heimberger, T., Schraud, H., Kressmann, S., Einsele, H., et al. (2013) · Haematologica · doi:10.3324/haematol.2012.066175 · Cited by 161
“The Hsp90-chaperone complex mediates the accurate conformation, stability and activity of many proteins, including key components of deregulated signaling pathways in tumor cells.(6,7) It has recently been shown that Hsp90 is frequently over-expressed in MM, sustains oncogenic deregulation of survival pathways, and cr…”
BackgroundHsp90 Selectively Modulates Phenotype in Vertebrate Development
Yeyati, P. L., Bancewicz, R. M., Maule, J., & van Heyningen, V. (2007) · PLoS Genetics · doi:10.1371/journal.pgen.0030043 · Cited by 157
“Selective degradation of mutant proteins through Hsp90 inhibition has been documented many times for different genes relevant for tumour progression [22].”
BackgroundPharmacodynamic Biomarkers for Molecular Cancer Therapeutics
(2006) · Advances in Cancer Research · doi:10.1016/s0065-230x(06)96008-4 · Cited by 161
Lavery, L. A., Partridge, J. R., Ramelot, T. A., Elnatan, D., Kennedy, M. A., & Agard, D. A. (2014) · Molecular Cell · doi:10.1016/j.molcel.2013.12.023 · Cited by 160
“Disruption of Hsp90 activity can affect evolutionary outcomes (Lindquist, 2009) and has been linked to human diseases, including cancer (Whitesell and Lindquist, 2005), vascular disease (Shah et al., 1999), and neurodegeneration (Luo et al., 2010).”
BackgroundSangster, T. A., Bahrami, A., Wilczek, A., Watanabe, E., Schellenberg, K., McLellan, C., Kelley, A., Kong, S. W., Queitsch, C., & Lindquist, S. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000648 · Cited by 160
“For example, as key proteins controlling cell proliferation depend on HSP90, it is an intensively investigated target for anti-cancer therapies [4].”
BackgroundSelf-citationDiscovery and development of heat shock protein 90 inhibitors
Taldone, T., Sun, W., & Chiosis, G. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.10.087 · Cited by 162
Min, J.-N., Huang, L., Zimonjic, D. B., Moskophidis, D., & Mivechi, N. F. (2007) · Oncogene · doi:10.1038/sj.onc.1210317 · Cited by 170
“…compromising essential cellular functions can result in disease, and based on the extensive literature on this topic, the critical involvement of Hsps in a wide range of human diseases, including cancer, has received especial attention (Jolly and Morimoto, 2000; Whitesell and Lindquist, 2005).”
BackgroundKrukenberg, K. A., Förster, F., Rice, L. M., Sali, A., & Agard, D. A. (2008) · Structure · doi:10.1016/j.str.2008.01.021 · Cited by 160
“Hsp90 binding also serves to protect some client proteins from ubiquitinylation and subsequent degradation (Caplan et al., 2007; Whitesell and Lindquist, 2005).”
Zhang, S., Binari, R., Zhou, R., & Perrimon, N. (2010) · Genetics · doi:10.1534/genetics.109.112516 · Cited by 160
Signalling and survival pathways in multiple myeloma
Bommert, K., Bargou, R. C., & Stühmer, T. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2005.12.026 · Cited by 158
The phosphatase Ppt1 is a dedicated regulator of the molecular chaperone Hsp90
Wandinger, S. K., Suhre, M. H., Wegele, H., & Büchner, J. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7600930 · Cited by 188
“Hsp90 is a ubiquitous and abundant molecular chaperone (Young et al, 2001; Picard, 2002; Prodromou and Pearl, 2003; Pratt and Toft, 2003; Wegele et al, 2004; Whitesell and Lindquist, 2005).”
Background
Metadata
- Authors
- Whitesell, L., & Lindquist, S. L.
- Affiliations
- University of Arizona (US)
- Whitehead Institute for Biomedical Research (US)
- Corresponding author
- Whitesell, Luke
- ORCID
- Whitesell, Luke
- Venue
- Nature Reviews Cancer
- Published
- 2005-09-20
- Volume
- 5
- Issue
- 10
- Pages
- 761-772
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2022531767
- Cited by
- 2,502
- References
- 149
- Citations by year
- 2026: 81 · 2025: 87 · 2024: 83 · 2023: 97 · 2022: 90 · 2021: 113 · 2020: 123 · 2019: 142 · 2018: 99 · 2017: 116 · 2016: 126 · 2015: 152 · 2014: 154 · 2013: 153 · 2012: 167
- FWCI
- 7.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Keywords
- HSP90, molecular chaperones, carcinogenesis, malignant transformation, somatic evolution, protein folding, proteome, anticancer drug targets, chaperone inhibition
- MeSH terms
- Animals, Humans, Neoplasms, Molecular Chaperones, HSP90 Heat-Shock Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.